Comparative study of increased plasma quinidine concentration in rats with glycerol- and cisplatin-induced acute renal failure

Drug Metabolism and Pharmacokinetics

Volumn 24, Issue 5, 2009, Pages 451-457

  Izuwa, Yuki ^a   Kusaba, Jun Ichi ^a   Horiuchi, Mizuki ^a   Aiba, Tetsuya ^a   Kawasaki, Hiromu ^a   Kurosaki, Yuji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Acute renal failure; Cisplatin; Glycerol; Quinidine; 1 acid glycoprotein

Indexed keywords

CISPLATIN; CREATININE; GLYCEROL; OROSOMUCOID; QUINIDINE; TOLBUTAMIDE;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; KIDNEY FUNCTION; LIVER METABOLISM; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; STEADY STATE; WISTAR RAT;

EID: 71449108675     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.24.451     Document Type: Article

References (40)

1. Kim, S. H., Shim, H. J., Kim, W. B. and Lee, M. G.: Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rats with uranyl nitrate-induced acute renal failure. Antimicrob. Agents Chemother., 42: 1217-1221 (1998).
2. Bowmer, C. J. and Lindup, W. E.: Decreased drug binding in uraemia: effect of indoxyl sulphate and other endogenous substances on the binding of drugs and dyes to human albumin. Biochem. Pharmacol., 31: 319-323 (1982).
3. Tsutsumi, Y., Maruyama, T., Takadate, A., Shimada, H. and Otagiri, M.: Decreased bilirubin-binding capacity in uremic serum caused by an accumulation of furan dicarboxylic acid. Nephron, 85: 60-64 (2000).
4. Vanholder, R., De Smet, R. and Lameire, N.: Protein-bound uremic solutes: the forgotten toxins. Kidney Int., 78: S266-270 (2001).
5. Boulton-Jones, J. M., Geddes, C. G., Heinzel, G., Turck, D., Nehmiz, G. and Bevis, P. J.: Meloxicam pharmacokinetics in renal impairment. Br. J. Clin. Pharmacol., 43: 35-40 (1997).
6. Van Peer, A., Belpaire, F. and Bogaert, M.: Pharmacokinetics of drugs in rabbits with experimental acute renal failure. Pharmacology, 17: 307-314 (1978).
7. Aiba, T., Horiuchi, M., Makita, T., Komori, Y., Kawasaki, H. and Kurosaki, Y.: Peritoneal dialysis alters tolbutamide pharmacokinetics in rats with experimental acute renal failure. Drug Metab. Pharmacokinet., 21, 291-296 (2006).
8. Pedersen, L. E., Bonde, J., Graudal, N. A., Backer, N. V., Hansen, J. E. and Kampmann, J. P.: Quantitative and qualitative binding characteristics of disopyramide in serum from patients with decreased renal and hepatic function. Br. J. Clin. Pharmacol., 23: 41-46 (1987).
9. Pere, P., Salonen, M., Jokinen, M., Rosenberg, P. H., Neuvonen, P. J. and Haasio, J.: Pharmacokinetics of ropivacaine in uremic and nonuremic patients after axillary brachial plexus block. Anesth. Analg., 96: 563-569 (2003).
10. Roy, L., Bannon, P., Villeneuve, J. P. and Leblanc, M.: Quinine pharmacokinetics in chronic haemodialysis patients. Br. J. Clin. Pharmacol., 54: 604-609 (2002).
11. Webb, D., Buss, D. C., Fifield, R., Bateman, D. N. and Routledge, P. A.: The plasma protein binding of metoclopramide in health and renal disease. Br. J. Clin. Pharmacol., 21: 334-336 (1986).
12. Crevoisier, C. A., Joseph, I., Fischer, M. and Graf, H.: Influence of hemodialysis on plasma concentration-time profiles of mefloquine in two patients with end-stage renal disease: a prophylactic drug monitoring study. Antimicrob. Agents Chemother., 39: 1892-1895 (1995).
13. Fremstad, D., Jacobsen, S. and Lunde, K. M.: Influence of serum protein binding on the pharmacokinetics of quinidine in normal and anuric rats. Acta Pharmacol. Toxicol., 41: 161-176 (1977).
14. Lili, C., Shibata, N., Yoshikawa, Y. and Takada, K.: Effect of glycerol-induced acute renal failure on the pharmacokinetics of lidocaine after transdermal application in rats. Biol. Pharm. Bull., 26: 1150-1154 (2003).
15. Terao, N. and Shen, D. D.: Effect of experimental renal failure on the disposition kinetics of l-propranolol in rats. J. Pharmacol. Exp. Ther., 227: 295-230 (1983).
16. Watari, N., Wakamatsu, A. and Kaneniwa, N.: Comparison of disposition parameters of quinidine and quinine in the rat. J. Pharmacobio-dyn., 12: 608-615 (1989).
17. Westenfelder, C., Arevalo, G. J., Crawford, P. W., Zerwer, P., Baranowski, R. L., Birch, F. M., Earnest, W. R., Hamburger, R. K., Coleman, R. D. and Kurtzman, N. A.: Renal tubular function in glycerol-induced acute renal failure. Kidney Int., 18: 432-444 (1980).
18. Zurovsky, Y.: Models of glycerol-induced acute renal failure in rats. J. Basic Clin. Physiol. Pharmacol., 4: 213-228 (1993).
19. Okabe, H., Hashimoto, Y. and Inui, K-I.: Pharmacokinetics and bioavailability of tacrolimus in rats with experimental renal dysfunction. J. Pharm. Pharmacol., 52: 1467-1472 (2000).
20. Chirino, Y. I., Sanchez-Gonzalez, D. J., Martinez-Martinez, C. M., Cruz, C., Pedraza-Chaverri, J.: Protective effects of apocynin against cisplatin-induced oxidative stress and nephrotoxicity. Toxicology, 245: 18-23 (2008).
21. Makita, T., Aiba, T., Izuwa, Y., Komori, Y., Kawasaki, H. and Kurosaki, Y.: Efficacy of peritoneal dialysis of tolbutamide in rats under conditions of the plasma unbound fraction being increased. Biopharm. Drug Dispos., 30: 1-8 (2009).
22. Aiba, T., Yoshinaga, M., Ishida, K., Takehara, Y. and Hashimoto, Y.: Intestinal expression and metabolic activity of the CYP3A subfamily in female rats. Biol. Pharm. Bull., 28: 311-315 (2005).
23. Sakae, R., Ishikawa, A., Niso, T., Komori, Y., Aiba, T., Kawasaki, H. and Kurosaki, Y.: Decreased lithium disposition to cerebrospinal fluid in rats with glycerol-induced acute renal failure. Pharm. Res., 25: 2243-2249 (2008).
24. Shibata, N., Shimakawa, H., Minouchi, T. and Yamaji, A.: Pharmacokinetics of cyclosporin A after intravenous administration to rats in various disease states. Biol. Pharm. Bull., 16: 1130-1135 (1993).
25. Okabe, H., Hasunuma, M. and Hashimoto, Y.: The hepatic and intestinal metabolic activities of P450 in rats with surgery- and drug-induced renal dysfunction. Pharm. Res., 20: 1591-1594 (2003).
26. Yasuhara, M., Fujiwara, J., Kitade, S., Katayama, H., Okumura, K. and Hori, R.: Effect of altered plasma protein binding on pharmacokinetics and pharmacodynamics of propranolol in rats after surgery: role of a1-acid glycoprotein. J. Pharmacol. Exp. Ther., 235: 513-520 (1985).
27. van Dijk, W., Pos, O., van der Stelt, M. E., Moshage, H. J., Yap, S. H., Dente, L., Baumann, P. and Eap, C. B.: Inflammation-induced changes in expression and glycosylation of genetic variants of a1-acid glycoprotein. Studies with human sera, primary cultures of human hepatocytes and transgenic mice. Biochem. J., 276: 343-347 (1991).
28. Sugihara, N., Furuno, K., Kita, N., Murakami, T. and Yata, N.: Plasma a1-acid glycoprotein concentration in rats with chemical liver injury. Chem. Pharm. Bull., 40: 2516-2519 (1992).
29. Baliga, R., Zhang, Z., Baliga, M. and Shah, S. V.: Evidence for cytochrome P-450 as a source of catalytic iron in myoglobinuric acute renal failure. Kidney Int., 49: 362-369 (1996).
30. Zager, R. A. and Burkhart, K.: Myoglobin toxicity in proximal human kidney cells: roles of Fe, Ca2, H2O2, and terminal mitochondrial electron transport. Kidney Int., 51: 728-738 (1997).
31. Baliga, R., Zhang, Z., Baliga, M., Ueda, N. and Shah, S. V.: In vitro and in vivo evidence suggesting a role for iron in cisplatin induced nephrotoxicity. Kidney Int., 53: 394-401 (1998).
32. Kawai, Y., Taniuchi, S., Okahara, S., Nakamura, M. and Gemba, M.: Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation. Biol. Pharm. Bull., 28: 1385-1388 (2005).
33. Yokoo, S., Yonezawa, A., Masuda, S., Fukatsu, A., Katsura, T. and Inui, K.: Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem. Pharmacol., 74: 477-487 (2007).
34. Baumann, H., Morella, K. K., Jahreis, G. P. and Marinkovi, S.: Distinct regulation of the interleukin-1 and interleukin-6 response elements of the rat haptoglobin gene in rat and human hepatoma cells. Mol. Cell Biol., 10: 5967-5976 (1990).
35. Kacevska, M., Robertson, G. R., Clarke, S. J. and Liddle, C.: Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opin. Drug Metab. Toxicol., 4: 137-149 (2008).
36. Okabe, H., Mizukami, A., Taguchi, M., Aiba, T., Yasuhara, M. and Hashimoto, Y.: The increased intestinal absorption rate is responsible for the reduced hepatic first-pass extraction of propranolol in rats with cisplatin-induced renal dysfunction. J. Pharm. Pharmacol., 55: 479-486 (2003).
37. Masubuchi, Y., Kawasaki, M. and Horie, T.: Down-regulation of hepatic cytochrome P450 enzymes associated with cisplatin-induced acute renal failure in male rats. Arch. Toxicol., 80: 347-353 (2006).
38. Ohishi, N., Imaoka, S. and Funae, Y.: Changes in content of P450 isozymes in hepatic and renal microsomes of the male rat treated with cis-diamminedichloroplatinum. Xenobiotica, 24: 873-880 (1994).
39. Litterst, C. L. and Magin, R.: Alterations in plasma pharmacokinetics of cisplatin in tumor-bearing rats. Cancer Chemother. Pharmacol., 22: 1-4 (1988).
40. Wang, K., Shindoh, H., Inoue, T. and Horii, I.: Advantages of in vitro cytotoxicity testing by using primary rat hepatocytes in comparison with established cell lines. J. Toxicol. Sci., 27: 229-237 (2002).